KALA BIO, Inc. (0JQ2.L) LSE
3.04
+0.06(+2.01%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.04
+0.06(+2.01%)
Currency In USD
Address
1167 Massachusetts Avenue
Arlington, MA 02476
United States of America (the)
Phone
781 996 5252
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
38
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Avi Minkowitz | CEO, CFO & Director | 0 | 1988 |
| R. Kim Brazzell | Head of R&D and Chief Medical Officer | 703,644 | 1953 |
| Todd Bazemore | Principal Executive Officer & Director | 732,507 | 1970 |
| Mary Reumuth | Treasurer & Secretary | 1.01M | 1975 |
| Carl Rennie | Executive Director of Account Management | 0 | N/A |
| Darius Kharabi | Chief Business Officer | 0 | 1980 |
| Josiah Craver | Senior Vice President & Corporate Controller | 0 | N/A |
| Patrick Bedell | Executive Director of Trade & Alternate Channels | 0 | N/A |
| Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | 0 | N/A |
| Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | 0 | 1963 |
| Francis S. Mah | Chief Medical Advisor | 0 | N/A |
| Justin Hanes | Founder & Chair of the Scientific Advisory Board | 0 | N/A |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.